1. Home
  2. KELYA vs LXEO Comparison

KELYA vs LXEO Comparison

Compare KELYA & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc.

KELYA

Kelly Services Inc.

HOLD

Current Price

$11.94

Market Cap

340.1M

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.50

Market Cap

369.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYA
LXEO
Founded
1946
2017
Country
United States
United States
Employees
4900
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
340.1M
369.8M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
KELYA
LXEO
Price
$11.94
$4.50
Analyst Decision
Buy
Strong Buy
Analyst Count
1
9
Target Price
$15.00
$18.44
AVG Volume (30 Days)
475.6K
631.3K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
39.81
EPS
N/A
N/A
Revenue
N/A
$654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.98
$3.60
52 Week High
$14.94
$10.99

Technical Indicators

Market Signals
Indicator
KELYA
LXEO
Relative Strength Index (RSI) 68.86 42.22
Support Level $8.30 $4.44
Resistance Level $12.01 $7.90
Average True Range (ATR) 0.44 0.30
MACD 0.01 -0.01
Stochastic Oscillator 84.21 39.29

Price Performance

Historical Comparison
KELYA
LXEO

About KELYA Kelly Services Inc.

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: